Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

Journal of Clinical Pharmacology

Volumn 55, Issue 12, 2015, Pages 1386-1394

  Zhuang, Yanli ^a   De Vries, Dick E ^b   Xu, Zhenhua ^a   Marciniak, Stanley J ^a   Chen, Dion ^a   Leon, Francisco ^a   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Janssen Biologics Europe   (Netherlands)

Author keywords

cocktail; human anti IL 6 monoclonal antibody; sirukumab; therapeutic protein drug interaction

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DRUG ANTIBODY; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MIDAZOLAM; OMEPRAZOLE; SIRUKUMAB; VITAMIN K GROUP; WARFARIN; CYTOCHROME P450; MONOCLONAL ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; ENZYME ACTIVITY; ERYTHEMA; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPHIL COUNT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SCREENING; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CAFFEINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDAZOLAM; MIDDLE AGED; OMEPRAZOLE; WARFARIN; YOUNG ADULT;

EID: 84954385879     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.561     Document Type: Article

References (23)

1. Zhou H, Meibohm B,. Drug interactions for therapeutic proteins: a journey just beginning. In: Zhou H, Meibohm B, eds. Drug-Drug Interactions for Therapeutic Biologics. Hoboken, NJ: Wiley; 2013: 1-4.
2. Guidance for Industry DISD, Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (draft), Center for Drug Evaluation and Research (CDER). February 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Accessed December 18, 2014.
3. Evers R, Dallas S, Dickmann LJ, et al., Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos. 2013; 41 (9): 1598-1609.
4. Kishimoto T., Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005; 23: 1-21.
5. Arend WP, Dayer JM,. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990; 33 (3): 305-315.
6. Abdel-Razzak Z, Loyer P, Fautrel A, et al., Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993; 44 (4): 707-715.
7. Aitken AE, Morgan ET,. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007; 35 (9): 1687-1693.
8. Zhang X, Schmitt C, Grange S, et al., Disease-Drug Interaction Studies of Tocilizumab with Cytochrome P450 Substrates In Vitro And In Vivo. Clin Pharmacol Ther. 2009; 85: S37-S64.
9. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S., Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011; 89 (5): 735-740.
10. Actemra [package insert]. South San Francisco, CA, Inc; 2014.
11. Fuhr U, Jetter A, Kirchheiner J., Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007; 81 (2): 270-283.
12. Zhou H, Tong Z, McLeod JF,. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol. 2004; 44 (2): 120-134.
13. Turpault S, Brian W, Van Horn R, et al., Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009; 68 (6): 928-935.
14. Chainuvati S, Nafziger AN, Leeder JS, et al., Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail." Clin Pharmacol Ther. 2003; 74 (5): 437-447.
15. Arnett FC, Edworthy SM, Bloch DA, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31 (3): 315-324.
16. Xu Z, Bouman-Thio E, Comisar C, et al., Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011; 72 (2): 270-281.
17. Zhuang Y, Xu Z, de Vries DE, et al., Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther. 2013; 51 (3): 187-199.
18. Dallas S, Chattopadhyay S, Sensenhauser C, Batheja A, Singer M, Silva J., Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes. Drug Metab Dispos. 2013; 41 (4): 689-693.
19. Jetter A, Fuhr U,. The cocktail approach and its utility in drug-drug interaction assessments for therapeutic proteins. In:, Zhou H, Meibohm B, eds. Drug-Drug Interactions for Therapeutic Biologics. Hoboken, Hoboken, NJ: Wiley; 2013: 111-118.
20. Machavaram KK, Almond LM, Rostami-Hodjegan A, et al., A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013; 94 (2): 260-268.
21. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014; 73 (9): 1616-1625.
22. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG,. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011; 39 (8): 1415-1422.
23. Dickmann LJ, Patel SK, Wienkers LC, Slatter JG,. Effects of interleukin 1beta (IL-1beta) and IL-1beta/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab. 2012; 13 (7): 930-937.